1 1

Anti-Human TIM-3 Monoclonal Antibody (Cobolimab)

Anti-Human TIM-3 Monoclonal Antibody (Cobolimab)

Catalog Number: UA016206 Brand: UA BIOSCIENCE
Share:
Price:
$615 USD
$615 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Human
Synonyms Cobolimab
Concentration 2mg/mL
Expression System HEK293
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4, containing no preservative
Stability & Storage

2 to 8 °C for 2 weeks under sterile conditions;

-20 °C for 3 months under sterile conditions;

-80 °C for 24 months under sterile conditions.

Please avoid repeated freeze-thaw cycles.
Reference

1. Falchook G S, Ribas A, Davar D, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. Journal of Clinical Oncology, 2022, 40(16_suppl): 2504.
2. Acoba J D, Rho Y, Fukaya E. Phase II study of cobolimab in combination with dostarlimab for the treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Oncology, 2023, 41(4_suppl): 580.
3. Davar D, Eroglu Z, Milhem M, et al. Combined targeting of PD-1 and TIM-3 in patients with locally advanced or metastatic non-small cell lung cancer: AMBER Part 2B[J]. Clinical Cancer Research, 2025, 31(16): 3443-3451.

Background

Cobolimab is a humanized monoclonal antibody targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Its unique mechanism involves binding to TIM-3 to induce receptor internalization, thereby blocking interactions with ligands such as Galectin-9, reversing T-cell exhaustion, and restoring anti-tumor immunity. Clinically, the AMBER trial (Phase I/II) evaluated cobolimab as monotherapy and in combination with PD-1 inhibitors (nivolumab or dostarlimab) in advanced solid tumors. The COSTAR Lung study further explored its potential with dostarlimab and docetaxel in non-small cell lung cancer, while a Phase II trial in hepatocellular carcinoma also demonstrated promising combination efficacy. Currently, cobolimab continues to be developed as a key TIM-3 pathway candidate in immuno-oncology combination strategies.

Picture

ELISA

Immobilized TIM-3/HAVCR2 Fc Chimera Protein, Human (Cat. No. UA010369) at 2.0μg/mL (100μL/well) can bind Biotinylated Anti-Human TIM-3 Monoclonal Antibody (Cobolimab) (Cat. No. UA016206) with EC50 of 0.98-1.31 ng/mL.